Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.45 |
| ▸ | RARG | P13631 | 5/20 | 0.45 |
| ▸ | RARA | P10276 | 4/20 | 0.45 |
| ▸ | RXRA | P19793 | 3/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | HNF4A | P41235 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713129 | 0.87 | RARB (0.36) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL9188117 | 0.84 | RARB (0.48) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL8081759 | 0.84 | RARB (0.45) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL4370337 | 0.81 | RARB (0.43) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL8089540 | 0.80 | MAP3K14 (0.37) | AKR1B1MAP3K14 | |
| SCHEMBL3456678 | 0.79 | RARB (0.51) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL9190581 | 0.79 | RARB (0.53) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL10557225 | 0.79 | RARB (0.44) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL29616597 | 0.78 | RARA (0.48) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL2599701 | 0.78 | RARA (0.48) | RARBRARGRARARXRACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| WO-2015107542-A2 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | disclosed |
| WO-2009116075-A2 | PROCESS FOR PREPARATION OF TAZAROTENE | INDOCO REMEDIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-20060205950-A1 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2006-09-14 | — | — | US | disclosed |
| EP-1700855-A1 | A process for the preparation of tazarotene | SOLMAG S.p.A. (IT) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006040644-A2 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED THIOCHROMAN DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-20 | — | — | WO | disclosed |
| US-6368608-B1 | SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) (FR) | 2002-04-09 | — | — | US | disclosed |
| US-5716624-A | USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS | C.I.R.D. GALDERMA (FR) | 1998-02-10 | — | — | US | disclosed |
| EP-0740665-A1 | PROCESS FOR PREPARING 4,4-DIALKYL-6-HALO-CHROMANS OR THIOCHROMANS USEFUL AS PHARMACEUTICAL INTERMEDIATES | Allergan (US) | 1996-11-06 | — | — | EP | disclosed |
| US-5519150-A | Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates | ALLERGAN (US) | 1996-05-21 | — | — | US | disclosed |
| EP-0405028-B1 | Thiochroman esters of phenols and terephthalates having retinoid-like activity | ALLERGAN INC (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1995019973-A2 | PROCESS FOR PREPARING 4,4-DIALKYL-6-HALO-CHROMANS OR THIOCHROMANS USEFUL AS PHARMACEUTICAL INTERMEDIATES | ALLERGAN (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0661258-A1 | Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
| US-5420295-A | Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates | ALLERGAN, INC. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5015658-A | Treatment of skin disorders such as psoriasis | ALLERGAN, INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0405028-A1 | Thiochroman esters of phenols and terephthalates having retinoid-like activity | ALLERGAN, INC (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4895868-A | PSORIASIS, SKIN DISORDERS, ANTIARTHRITIC, WOUND HEALING, EYE DRYNESS | ALLERGAN, INC. (US) | 1990-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205950-A1 | Process for the preparation of Tazarotene | DHPS, COASY, STS | RARB 1324/4885RARG 1550/4885RARA 1663/4885 |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | PPIA, CUTA, TFPI | RARB 130/4885RARG 294/4885RARA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.